keyword
https://read.qxmd.com/read/38523706/rifampicin-resistant-mycobacterium-tuberculosis-in-vietnam-2020-2022
#1
JOURNAL ARTICLE
Hung Van Nguyen, Hoa Binh Nguyen, Doan Thu Ha, Dinh Thi Huong, Vu Ngoc Trung, Khieu Thi Thuy Ngoc, Tran Huyen Trang, Ha Vu Thi Ngoc, Tram Trinh Thi Bich, Trieu Le Pham Tien, Hanh Nguyen Hong, Phu Phan Trieu, Luong Kim Lan, Kim Lan, Ngo Ngoc Hue, Nguyen Thi Le Huong, Tran Le Thi Ngoc Thao, Nguyen Le Quang, Thu Do Dang Anh, Nguyễn Hữu Lân, Truong Van Vinh, Dang Thi Minh Ha, Phan Thuong Dat, Nguyen Phuc Hai, Derrick W Crook, Nguyen Thuy Thuong Thuong, Nhung Viet Nguyen, Guy E Thwaites, Timothy M Walker
OBJECTIVE: We conducted a descriptive analysis of multi-drug resistant tuberculosis (MDR-TB) in Vietnam's two largest cities, Hanoi and Ho Chi Minh city. METHODS: All patients with rifampicin resistant tuberculosis were recruited from Hanoi and surrounding provinces between 2020 and 2022. Additional patients were recruited from Ho Chi Minh city over the same time period. Demographic data were recorded from all patients, and samples collected, cultured, whole genome sequenced and analysed for drug resistance mutations...
May 2024: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
https://read.qxmd.com/read/38515382/fetal-protective-effect-of-indonesian-propolis-from-apis-mellifera-against-rifampicin-pyrazinamide-induced-impaired-pregnancy-in-balb-c-mice
#2
JOURNAL ARTICLE
Rahmad Abdillah, Fitri Rachmaini, Dinda Fadhilah, Almahdy Almahdy
OBJECTIVE: Anti-tuberculosis drugs Rifampicin and Pyrazinamide combination in pregnancy can cause morphological, visceral and skeletal damage. Several studies showed that propolis improves pregnancy outcomes. This study aims to determine the fetal protective effect of propolis in BALB/c mice given the anti-tuberculosis drug combination Rifampicin and Pyrazinamide. METHODS: A total of 21 pregnant mice were randomly divided into three groups: the normal group (N) was given distilled water as a vehicle, the positive control group (RP) were given rifampicin 15 mg/kg BW, pyrazinamide 35 mg/kg BW and the treatment group (IP) were given rifampicin 15 mg/kg BB, pyrazinamide 35 mg/kg BW and propolis 400 mg/kg BW...
March 25, 2024: Journal of Complementary & Integrative Medicine
https://read.qxmd.com/read/38500518/prediction-of-pyrazinamide-resistance-in-mycobacterium-tuberculosis-using-structure-based-machine-learning-approaches
#3
JOURNAL ARTICLE
Joshua J Carter, Timothy M Walker, A Sarah Walker, Michael G Whitfield, Glenn P Morlock, Charlotte I Lynch, Dylan Adlard, Timothy E A Peto, James E Posey, Derrick W Crook, Philip W Fowler
BACKGROUND: Pyrazinamide is one of four first-line antibiotics used to treat tuberculosis; however, antibiotic susceptibility testing for pyrazinamide is challenging. Resistance to pyrazinamide is primarily driven by genetic variation in pncA , encoding an enzyme that converts pyrazinamide into its active form. METHODS: We curated a dataset of 664 non-redundant, missense amino acid mutations in PncA with associated high-confidence phenotypes from published studies and then trained three different machine-learning models to predict pyrazinamide resistance...
April 2024: JAC-antimicrobial resistance
https://read.qxmd.com/read/38499243/bilateral-endoscopic-debridement-combined-with-local-antituberculosis-drugs-for-thoracic-tuberculosis-with-large-paravertebral-abscess-a-multicenter-study-with-4-year-follow-up
#4
JOURNAL ARTICLE
Jian Kang, Xiujia Xia, Rong'an Shang, Xiaoming Wang, Panju Cao, Junfeng Wang, Jie Zhang, Wanli Feng, Jianmin Wei, Qiaolong Hu
BACKGROUND: Paravertebral abscess represents a prevalent manifestation of thoracic tuberculosis, often necessitating surgical intervention. In this study, we introduced a novel approach by employing bilateral endoscopic debridement to address large Paravertebral abscesses associated with thoracic tuberculosis, a method not previously proposed in the literature. The clinical efficacy was examined through a comprehensive 4-year follow-up. METHODS: We conducted a retrospective analysis on patients diagnosed with thoracic tuberculosis and paravertebral abscess (TB-PA) who underwent bilateral endoscopic debridement combined with local antituberculosis drugs (BED+LAD) between February 2015 and February 2019...
March 16, 2024: World Neurosurgery
https://read.qxmd.com/read/38495513/rapid-detection-of-multidrug-resistance-in-tuberculosis-using-nanopore-based-targeted-next-generation-sequencing-a-multicenter-double-blind-study
#5
JOURNAL ARTICLE
Aimei Liu, Sang Liu, Kangyan Lv, Qingdong Zhu, Jun Wen, Jianpeng Li, Chengyuan Liang, Xuegang Huang, Chunming Gong, Qingfeng Sun, Hongcang Gu
BACKGROUND: Resistance to anti-tuberculous drugs is a major challenge in the treatment of tuberculosis (TB). We aimed to evaluate the clinical availability of nanopore-based targeted next-generation sequencing (NanoTNGS) for the diagnosis of drug-resistant tuberculosis (DR-TB). METHODS: This study enrolled 253 patients with suspected DR-TB from six hospitals. The diagnostic efficacy of NanoTNGS for detecting Mycobacterium tuberculosis and its susceptibility or resistance to first- and second-line anti-tuberculosis drugs was assessed by comparing conventional phenotypic drug susceptibility testing (pDST) and Xpert MTB/RIF assays...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38489738/impact-of-delayed-diagnosis-and-treatment-on-tuberculosis-infection-within-families-a-case-report
#6
JOURNAL ARTICLE
Jian-Jun Liu, Yin-Ping Feng, Zhong-Da Liu, Jing Guo
BACKGROUND: A 32-year-old male patient was diagnosed with a 30% left pneumothorax on November 5, 2020, during which chest imaging indicated abnormalities. Despite this, pulmonary tuberculosis (TB) was not diagnosed or treated at that time due to a negative result in the MGIT960 culture. The patient experienced symptoms of cough and expectoration on April 24, 2022. Upon repeating the chest imaging, the condition had worsened, confirming the presence of pulmonary TB, leading to the patient's hospitalization...
March 15, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38482083/rare-case-of-mycobacterium-avium-complex-peritonitis-in-a-patient-with-multiple-myeloma-undergoing-peritoneal-dialysis
#7
Sacide S Ozgur, Nida Ansari, Dhruv Patel, Ryan Rahman, Raymond Shih
Mycobacterium avium complex (MAC) infections can present as a variety of severe diseases. While it has a predilection for immunocompromised patients such as those with Human immunodeficiency virus (HIV), it can also affect immunocompetent patients as well. One of the rare yet severe diseases that MAC infections can present is MAC peritonitis. Often hard to distinguish from other causes of peritonitis, high clinical suspicion should be maintained for those who are susceptible. Here we present an 85-year-old female with a past medical history of end-stage renal disease on peritoneal dialysis who presented with nausea and vomiting...
2024: Journal of Community Hospital Internal Medicine Perspectives
https://read.qxmd.com/read/38466092/targeted-sequencing-from-cerebrospinal-fluid-for-rapid-identification-of-drug-resistant-tuberculous-meningitis
#8
JOURNAL ARTICLE
Trinh Thi Bich Tram, Le Pham Tien Trieu, Le Thanh Hoang Nhat, Do Dang Anh Thu, Nguyen Le Quang, Nguyen Duc Bang, Tran Thi Hong Chau, Guy E Thwaites, Timothy M Walker, Vu Thi Ngoc Ha, Nguyen Thuy Thuong Thuong
Mortality from tuberculous meningitis (TBM) remains around 30%, with most deaths occurring within 2 months of starting treatment. Mortality from drug-resistant strains is higher still, making early detection of drug resistance (DR) essential. Targeted next-generation sequencing (tNGS) produces high read depths, allowing the detection of DR-associated alleles with low frequencies. We applied Deeplex Myc-TB-a tNGS assay-to cerebrospinal fluid (CSF) samples from 72 adults with microbiologically confirmed TBM and compared its genomic drug susceptibility predictions to a composite reference standard of phenotypic susceptibility testing (pDST) and whole genome sequencing, as well as to clinical outcomes...
March 11, 2024: Journal of Clinical Microbiology
https://read.qxmd.com/read/38461874/triple-combination-dry-powder-formulation-of-pretomanid-moxifloxacin-and-pyrazinamide-for-treatment-of-multidrug-resistant-tuberculosis
#9
JOURNAL ARTICLE
Claire Fan, Basanth Babu Eedara, Shubhra Sinha, Mohammad Khaja Mafij Uddin, Colin Doyle, Sayera Banu, Shyamal C Das
Both latent and multidrug-resistant tuberculosis (TB) have been causing significant concern worldwide. A novel drug, pretomanid (PA-824), has shown a potent bactericidal effect against both active and latent forms of Mycobacterium tuberculosis (MTb) and a synergistic effect when combined with pyrazinamide and moxifloxacin. This study aimed to develop triple combination spray dried inhalable formulations composed of antitubercular drugs, pretomanid, moxifloxacin, and pyrazinamide (1:2:8 w/w/w), alone (PaMP) and in combination with an aerosolization enhancer, L-leucine (20 % w/w, PaMPL)...
March 8, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38453976/the-prevalence-clinical-reasoning-and-impact-of-non-standard-anti-tuberculosis-regimens-at-the-initial-prescription
#10
JOURNAL ARTICLE
Rou-Tsern Chen, Chih-Yu Liu, Shu-Yung Lin, Chin-Chung Shu, Wang-Huei Sheng
Regarding clinically-concerning non-standard initial anti-tuberculous (TB) regimens, few studies have examined their prevalence, risk factors and impacts. We recruited patients with drug susceptible TB and non-standard initial anti-TB regimens (NSTB group) and matched them with patients with standard initial regimens (STB group) in a 1:1 ratio. The risk factors and outcomes were analyzed. During the 11-year study period, we analyzed 50 (3.7%) patients with NSTB from a total set of 1337 patients with drug-susceptible TB...
March 7, 2024: Scientific Reports
https://read.qxmd.com/read/38433783/retrospective-analysis-of-the-efficacy-and-safety-of-endoscopic-spinal-tuberculosis-focus-removal-versus-posterior-pedicle-lesion-removal-bone-grafting-and-internal-fixation-combined-with-drug-chemotherapy-for-thoracolumbar-tuberculosis
#11
JOURNAL ARTICLE
Tuerhongjian Abudurexiti, Abuduwupuer Haibier, Alimujiang Yusufu, Kutiluke Shoukeer, Hang Lin
OBJECTIVE: This study aims to investigate the clinical efficacy of endoscopic spinal tuberculosis focus removal, posterior pedicle lesion removal, bone grafting, and internal fixation combined with drug chemotherapy in treating thoracolumbar tuberculosis. It also seeks to summarize strategies for preventing complications and provide a reference for clinical treatment. METHODS: We retrospectively analyzed 105 patients with spinal tuberculosis treated in our hospital from January 2018 to December 2022...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38429734/changes-of-mycobacterium-tuberculosis-specific-antigen-stimulated-cd27-cd38-ifn-%C3%AE-cd4-t-cells-before-and-after-anti-tuberculosis-treatment
#12
JOURNAL ARTICLE
Yong Fang, Yuan Tang, Qiao-Xia Luo, Na Wang, Liang Tang, Xiao-Jun Yang, Xiao-Fang You, Yu-Chun Wang, Li Liang, Jing-Bo Zhang, Bo Su, Wei Sha
BACKGROUND: The aim of the study was to investigate whether the expression of CD27- CD38+ in interferon (IFN)-γ+ CD4+ T cells stimulated by the specific antigen early secreted antigenic target-6 (ESAT-6)/culture filter protein-10 (CFP-10) could be a potential new therapeutic evaluation indicator for anti-tuberculosis (TB) treatment. METHODS: Newly diagnosed active pulmonary TB patients, latent TB infection (LTBI) and healthy controls were enrolled from January 2021 to December 2021...
March 1, 2024: European Journal of Medical Research
https://read.qxmd.com/read/38422295/exploring-of-pyrazinamidase-recombinant-activity-from-pza-sensitive-and-resistant-mycobacterium-tuberculosis-expressed-in-escherichia-coli-bl21-de3
#13
JOURNAL ARTICLE
P Purkan, S Hadi, W Retnowati, S Sumarsih, D K Wahyuni, B Piluharto, T M Panjaitan, C Ifada, A Nadila, B A Nabilah
The mutations of pncA gene encoding pyrazinamidase/PZase in Mycobacterium tuberculosis are often associated with pyrazinamide/PZA resistance. The H and R1 isolates showed significant phenotypic differences to PZA. The H isolate was PZA sensitive, but R1 was PZA resistant up to 100 ug/ml. The paper reports the pncA profile for both isolates and the activity of their protein expressed in Escherichia coli BL21(DE3). The 0.6 kb of each pncA genes have been subcloned successfully into the 5.4 kb pET30a vector and formed the pET30a-pncA recombinant with a size of 6...
2024: Brazilian Journal of Biology
https://read.qxmd.com/read/38414662/pyrazinoic-acid-the-active-form-of-the-anti-tuberculosis-drug-pyrazinamide-and-aromatic-carboxylic-acid-analogs-are-protonophores
#14
JOURNAL ARTICLE
Fabio L Fontes, Steven A Rooker, Jamie K Lynn-Barbe, Michael A Lyons, Debbie C Crans, Dean C Crick
Pyrazinoic acid is the active form of pyrazinamide, a first-line antibiotic used to treat Mycobacterium tuberculosis infections. However, the mechanism of action of pyrazinoic acid remains a subject of debate, and alternatives to pyrazinamide in cases of resistance are not available. The work presented here demonstrates that pyrazinoic acid and known protonophores including salicylic acid, benzoic acid, and carbonyl cyanide m -chlorophenyl hydrazone all exhibit pH-dependent inhibition of mycobacterial growth activity over a physiologically relevant range of pH values...
2024: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/38404200/a-systematic-efficacy-analysis-of-tuberculosis-treatment-with-bpal-containing-regimens-using-a-multiscale-modeling-approach
#15
JOURNAL ARTICLE
Maral Budak, Laura E Via, Danielle M Weiner, Clifton E Barry, Pariksheet Nanda, Gabrielle Michael, Khisimuzi Mdluli, Denise Kirschner
Tuberculosis (TB) is a life-threatening infectious disease. The standard treatment is up to 90% effective; however, it requires the administration of four antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol [HRZE]) over long time periods. This harsh treatment process causes adherence issues for patients because of the long treatment times and a myriad of adverse effects. Therefore, the World Health Organization has focused goals of shortening standard treatment regimens for TB in their End TB Strategy efforts, which aim to reduce TB-related deaths by 95% by 2035...
February 26, 2024: CPT: Pharmacometrics & Systems Pharmacology
https://read.qxmd.com/read/38402260/mesenchymal-stem-cells-derived-extracellular-vesicles-for-therapeutics-of-renal-tuberculosis
#16
JOURNAL ARTICLE
Natalia Yudintceva, Danila Bobkov, Maksim Sulatsky, Natalia Mikhailova, Elena Oganesyan, Tatiana Vinogradova, Alexandr Muraviov, Anna Remezova, Evdokia Bogdanova, Irina Garapach, Olga Maslak, Dilyara Esmedlyaeva, Marina Dyakova, Petr Yablonskiy, Rustam Ziganshin, Sergey Kovalchuk, Natalya Blum, Shirish H Sonawane, Avinash Sonawane, Ankita Behl, Shailja Singh, Maxim Shevtsov
Extrapulmonary tuberculosis with a renal involvement can be a manifestation of a disseminated infection that requires therapeutic intervention, particularly with a decrease in efficacy of conventional regimens. In the present study, we investigated the therapeutic potency of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in the complex anti-tuberculosis treatment (ATT). A rabbit model of renal tuberculosis (rTB) was constructed by injecting of the standard strain Mycobacterium tuberculosis H37Rv into the cortical layer of the kidney parenchyma...
February 24, 2024: Scientific Reports
https://read.qxmd.com/read/38395123/cryo-em-structures-of-mycobacterium-tuberculosis-polynucleotide-phosphorylase-suggest-a-potential-mechanism-for-its-rna-substrate-degradation
#17
JOURNAL ARTICLE
Na Wang, Yanan Sheng, Yutong Liu, Yaoting Guo, Jun He, Jinsong Liu
As one of the oldest infectious diseases in the world, tuberculosis (TB) is the second most deadly infectious disease after COVID-19. Tuberculosis is caused by Mycobacterium tuberculosis (Mtb), which can attack various organs of the human body. Up to now, drug-resistant TB continues to be a public health threat. Pyrazinamide (PZA) is regarded as a sterilizing drug in the treatment of TB due to its distinct ability to target Mtb persisters. Previously we demonstrated that a D67 N mutation in Mycobacterium tuberculosis polynucleotide phosphorylase (MtbPNPase, Rv2783c) confers resistance to PZA and Rv2783c is a potential target for PZA, but the mechanism leading to PZA resistance remains unclear...
February 21, 2024: Archives of Biochemistry and Biophysics
https://read.qxmd.com/read/38391403/the-interplay-between-mycobacterium-tuberculosis-and-human-microbiome
#18
REVIEW
Michelle Nguyen, Phillip Ahn, John Dawi, Areg Gargaloyan, Anthony Kiriaki, Tiffany Shou, Kevin Wu, Kian Yazdan, Vishwanath Venketaraman
Tuberculosis (TB), a respiratory disease caused by Mycobacterium tuberculosis (Mtb), is a significant cause of mortality worldwide. The lung, a breeding ground for Mtb, was once thought to be a sterile environment, but has now been found to host its own profile of microbes. These microbes are critical in the development of the host immune system and can produce metabolites that aid in host defense against various pathogens. Mtb infection as well as antibiotics can shift the microbial profile, causing dysbiosis and dampening the host immune response...
January 24, 2024: Clinics and Practice
https://read.qxmd.com/read/38390619/evaluation-of-sulfasalazine-as-an-adjunctive-therapy-in-treating-pulmonary-pre-xdr-tb-efficacy-safety-and-treatment-implication
#19
JOURNAL ARTICLE
Liang Fu, Wenfei Wang, Juan Xiong, Peize Zhang, Hui Li, Xilin Zhang, Hancheng Liang, Qianting Yang, Zhaoqin Wang, Xinchun Chen, Guofang Deng, Yi Cai, Shenjie Tang
BACKGROUND: The rising prevalence and limited efficacy of treatments for pre-extensively drug-resistant tuberculosis (pre-XDR-TB) underscore an immediate need for innovative therapeutic options. A combination of host-directed therapy (HDT) and anti-TB treatment presents a viable alternative for pre-XDR-TB management. Sulfasalazine (SASP), by targeting the amino acid transport system xc (xCT), potentially reduces the intracellular Mycobacterium tuberculosis load and mitigates lung pathology, positioning it as a promising TB HDT agent...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38381052/polymorphic-structure-determination-of-the-macrocyclic-drug-paritaprevir-by-microed
#20
JOURNAL ARTICLE
Guanhong Bu, Emma Danelius, Lianne H E Wieske, Tamir Gonen
Paritaprevir is an orally bioavailable, macrocyclic drug used for treating chronic Hepatitis C virus (HCV) infection. Its structures have been elusive to the public until recently when one of the crystal forms is solved by microcrystal electron diffraction (MicroED). In this work, the MicroED structures of two distinct polymorphic crystal forms of paritaprevir are reported from the same experiment. The different polymorphs show conformational changes in the macrocyclic core, as well as the cyclopropyl sulfonamide and methyl pyrazinamide substituents...
February 21, 2024: Advanced biology
keyword
keyword
109660
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.